Cartesian Therapeutics, Inc. (RNAC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-15M 0 15M 30M 45M Q3 '16: 1M Q4 '16: 2.9M Q1 '17: 137K Q2 '17: 26K Q3 '17: 27K Q4 '17: 17K Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 903K Q1 '19: 10K Q2 '19: 13K Q3 '19: 0 Q4 '19: 6.7M Q1 '20: 0 Q2 '20: 0 Q3 '20: 4.6M Q4 '20: 12M Q1 '21: 11.1M Q2 '21: 19.7M Q3 '21: 24.4M Q4 '21: 29.9M Q1 '22: 34M Q2 '22: 39.3M Q3 '22: 20.7M Q4 '22: 16.8M Q1 '23: 5.9M Q2 '23: 5.2M Q3 '23: 6.6M Q4 '23: 8.3M Q1 '24: 5.8M Q2 '24: 33.4M Q3 '24: 387K Q4 '24: -759K Q1 '25: 1.1M Q2 '25: 298K Q3 '25: 452K Q4 '25: 947K Q1 '26: 78K Q2 '26: 0 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '16: -7.5M Q4 '16: -13.9M Q1 '17: -14.8M Q2 '17: -15.9M Q3 '17: -13.9M Q4 '17: -19.3M Q1 '18: -15.8M Q2 '18: -18.8M Q3 '18: -15.9M Q4 '18: -14.5M Q1 '19: -11.9M Q2 '19: -16.2M Q3 '19: -11.8M Q4 '19: -12.6M Q1 '20: -18.8M Q2 '20: -16.4M Q3 '20: -13.7M Q4 '20: -7.9M Q1 '21: -7.2M Q2 '21: 452K Q3 '21: -2M Q4 '21: 4.1M Q1 '22: 10.8M Q2 '22: 13.9M Q3 '22: -1.6M Q4 '22: -8.5M Q1 '23: -18.4M Q2 '23: -18.6M Q3 '23: -13.1M Q4 '23: -36.3M Q1 '24: -13.3M Q2 '24: 13.8M Q3 '24: -17.6M Q4 '24: -26.7M Q1 '25: -21.9M Q2 '25: -21.8M Q3 '25: -21.1M Q4 '25: -78.6M Q1 '26: -26.5M Q2 '26: -29.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '16: -7.7M Q4 '16: -14.1M Q1 '17: -15.1M Q2 '17: -16M Q3 '17: -14.7M Q4 '17: -19.5M Q1 '18: -15.9M Q2 '18: -18.8M Q3 '18: -16M Q4 '18: -14.7M Q1 '19: -12.1M Q2 '19: -16.4M Q3 '19: -12M Q4 '19: -14.9M Q1 '20: -19.6M Q2 '20: -24.1M Q3 '20: -9.7M Q4 '20: -15.4M Q1 '21: -24.6M Q2 '21: 4.6M Q3 '21: -17.9M Q4 '21: 12.2M Q1 '22: 28.8M Q2 '22: 8.6M Q3 '22: -7.9M Q4 '22: 13.2M Q1 '23: -21.7M Q2 '23: -11.4M Q3 '23: -9M Q4 '23: -177.7M Q1 '24: -56.8M Q2 '24: 13.8M Q3 '24: -24.2M Q4 '24: -10.3M Q1 '25: -17.7M Q2 '25: 15.9M Q3 '25: -35.9M Q4 '25: -92.6M Q1 '26: -39.2M Q2 '26: 15.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-50M -25M 0 25M 50M 75M Q3 '16: -5.5M Q4 '16: 1.5M Q1 '17: -15.3M Q2 '17: -8.6M Q3 '17: -15.4M Q4 '17: -12.7M Q1 '18: -13.4M Q2 '18: -17M Q3 '18: -16M Q4 '18: -12.7M Q1 '19: -20.2M Q2 '19: -7.2M Q3 '19: -11.1M Q4 '19: -12.9M Q1 '20: -11.7M Q2 '20: -11.8M Q3 '20: 65.6M Q4 '20: -7.2M Q1 '21: -12.1M Q2 '21: -6M Q3 '21: -10.7M Q4 '21: -31.5M Q1 '22: -11.9M Q2 '22: -12.3M Q3 '22: 4.4M Q4 '22: -11.8M Q1 '23: -8.8M Q2 '23: -9.9M Q3 '23: -9.2M Q4 '23: -23.3M Q1 '24: -15.9M Q2 '24: -14.4M Q3 '24: 13.7M Q4 '24: -7M Q1 '25: -23.1M Q2 '25: -17.5M Q3 '25: -15.6M Q4 '25: -17.7M Q1 '26: -22.1M Q2 '26: -21.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-50M -25M 0 25M 50M 75M Q3 '16: -5.7M Q4 '16: 1.4M Q1 '17: -15.4M Q2 '17: -9M Q3 '17: -15.6M Q4 '17: -12.8M Q1 '18: -13.6M Q2 '18: -17.2M Q3 '18: -16.1M Q4 '18: -13.1M Q1 '19: -20.2M Q2 '19: -7.2M Q3 '19: -11.1M Q4 '19: -12.9M Q1 '20: -11.8M Q2 '20: -12M Q3 '20: 65.3M Q4 '20: -7.4M Q1 '21: -12.2M Q2 '21: -6.7M Q3 '21: -10.9M Q4 '21: -31.7M Q1 '22: -12.3M Q2 '22: -12.4M Q3 '22: 3.9M Q4 '22: -12.1M Q1 '23: -8.9M Q2 '23: -9.9M Q3 '23: -9.2M Q4 '23: -23.4M Q1 '24: -16.5M Q2 '24: -16M Q3 '24: 7.5M Q4 '24: -7.7M Q1 '25: -24.2M Q2 '25: -20.1M Q3 '25: -16.9M Q4 '25: -18.2M Q1 '26: -22.2M Q2 '26: -21.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '20: 96.8M Q3 '20: 105.3M Q1 '21: 110.7M Q2 '21: 121.2M Q3 '21: 115.2M Q1 '22: 127.6M Q2 '22: 148.5M Q3 '22: 152.8M Q1 '23: 5.1M Q2 '23: 5.1M Q3 '23: 5.2M Q1 '24: 5.4M Q2 '24: 17.8M Q3 '24: 21.5M Q1 '25: 25.9M Q2 '25: 26.4M Q3 '25: 26M Q1 '26: 26.9M Q2 '26: 29.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '15: -15.12 Q1 '16: -16.21 Q2 '16: -15.03 Q3 '16: -11.96 Q4 '16: -8.47 Q1 '17: -4.77 Q2 '17: -2.87 Q3 '17: -3.10 Q4 '17: -3.21 Q1 '18: -3.10 Q2 '18: -3.09 Q3 '18: -3.14 Q4 '18: -2.91 Q1 '19: -2.51 Q2 '19: -2.04 Q3 '19: -1.59 Q4 '19: -1.22 Q1 '20: -1.12 Q2 '20: -1.00 Q3 '20: -0.83 Q4 '20: -0.69 Q1 '21: -0.70 Q2 '21: -0.45 Q3 '21: -0.52 Q4 '21: -0.22 Q1 '22: 0.08 Q2 '22: 0.14 Q3 '22: 0.25 Q4 '22: 0.10 Q1 '23: -4.22 Q2 '23: -6.51 Q3 '23: -8.20 Q4 '23: -49.77 Q1 '24: -56.03 Q2 '24: -53.26 Q3 '24: -52.65 Q4 '25: -5.13 Q1 '26: -5.91 Q2 '26: -5.95 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.